Introduction to Imricor's latest announcement

Imricor Medical Systems, Inc. (ASX: $IMR) has received its first catheter order from Dubrava University Hospital in Zagreb, Croatia. The hospital has ordered the first set of Imricor catheters and other consumable devices, with procedures expected to commence in May. The MRI system at Dubrava required a software upgrade to enable real-time imaging, which is scheduled for installation this month. Imricor personnel will complete the site's final training, and under the procurement contract, Dubrava will order a minimum of 50 procedures worth of consumable product each year from Imricor.

Executive Commentary on the Latest Development

Imricor's Chair and CEO, Steve Wedan, expressed his delight at receiving the first purchase order from Dubrava, highlighting the potential for steady revenue growth throughout the year. He emphasized the significance of activating new hospitals, generating consumable revenue from atrial flutter procedures, and establishing an installed base for future revenue expansion. Wedan also expressed confidence in the company's ability to continue activating sites and adding new sites to the sales pipeline.

Summary of Imricor's Announcement

Imricor Medical Systems, Inc. (ASX: $IMR) has successfully received its first catheter order from Dubrava University Hospital, marking a significant milestone in the company's European sales strategy for 2024. The order includes the first set of Imricor catheters and other consumable devices, with procedures set to commence in May following the installation of the required MRI software upgrade. The procurement contract stipulates that Dubrava will order a minimum of 50 procedures worth of consumable product each year from Imricor, aligning with the site's goal to increase the number of ablation procedures performed annually. Imricor's Chair and CEO, Steve Wedan, expressed optimism about the company's future revenue expansion and the continued success of activating new sites. The company aims to establish steady revenue growth throughout the year, reflecting its commitment to making a meaningful impact on patients, healthcare professionals, and healthcare facilities worldwide by increasing the success rates and reducing the overall costs of cardiac ablation procedures.